For patients with chronic dry eye disease, long-term pharmacologic management is often essential—but conventional preserved eye drops can inadvertently worsen the very condition they aim to treat. Repeated exposure to preservatives such as benzalkonium chloride (BAK) has been well documented to cause cumulative toxicity to corneal and conjunctival epithelial cells, leading to increased ocular surface inflammation, persistent dryness, and conjunctival hyperemia. This creates a paradoxical clinical scenario: “the more you treat, the drier it gets.” As a result, clinicians and patients alike are increasingly seeking therapeutic alternatives that deliver sustained anti-inflammatory efficacy without compromising ocular surface integrity.
Among emerging options, preservative-free low-concentration cyclosporine A ophthalmic solution—specifically Zirun Cyclosporine Eye Drops (II)—has emerged as a first-line, evidence-based choice for long-term dry eye management. Endorsed by the 2024 Chinese Expert Consensus on Clinical Diagnosis and Treatment of Dry Eye and aligned with the 2026 International Clinical Practice Guidelines for Dry Eye, this formulation addresses three critical therapeutic imperatives: safety over extended use, mechanistic disease modification, and reduction of symptomatic treatment dependency.
Preservative-free delivery eliminates cumulative epithelial toxicity. Unlike multi-dose preserved formulations, Zirun Cyclosporine Eye Drops (II) contains no antimicrobial agents and is supplied in single-use, sterile vials. Each dose is administered once and discarded—eliminating the risk of BAK-induced goblet cell loss, epithelial barrier disruption, and subclinical limbal stem cell damage. This design is particularly advantageous for patients requiring continuous anti-inflammatory therapy over months or years, as recommended in moderate-to-severe aqueous-deficient or inflammatory dry eye.
Targeted anti-inflammatory action restores endogenous tear function. At a concentration of 0.05% cyclosporine A, the agent selectively inhibits T-lymphocyte activation and downstream pro-inflammatory cytokine release (e.g., IL-2, IFN-γ) on the ocular surface. Clinical studies demonstrate that sustained use promotes lacrimal gland secretion, enhances mucin production by conjunctival goblet cells, and improves tear film stability—leading to measurable reductions in reliance on artificial tears. Unlike symptomatic lubricants, this mechanism targets the underlying immunopathology of dry eye, supporting gradual tapering of adjunctive tear supplementation under clinical supervision.
Favorable long-term safety profile supports maintenance therapy. Large-scale clinical experience and consensus guidelines confirm that low-dose cyclosporine A is well tolerated with minimal systemic absorption and negligible ocular adverse effects beyond transient mild stinging. When used consistently per protocol—twice daily to maintain therapeutic intraocular concentrations—it effectively slows disease progression, reduces frequency of acute exacerbations, and stabilizes tear film osmolarity and breakup time over time. This makes it especially suitable for patients with Sjögren’s syndrome, post-cataract surgery dry eye, or screen-related evaporative dry eye with significant inflammatory components.
For optimal outcomes, clinicians recommend integrating Zirun Cyclosporine Eye Drops (II) into a comprehensive management strategy: pairing it with preservative-free artificial tears for immediate symptom relief; avoiding unregulated “fatigue-relieving” or vasoconstrictor-containing over-the-counter drops; maintaining consistent sleep hygiene and blink-aware digital device use; and scheduling structured follow-up every 3–6 months—including tear film osmolarity testing, meibomian gland evaluation, and ocular surface staining—to guide individualized treatment escalation or de-escalation.
Common clinical questions:
Q: Does preservative-free packaging compromise sterility or shelf life?
A: No. The single-dose vial remains stable and sterile until opened. Once opened, the entire contents must be used immediately—eliminating concerns about microbial contamination or chemical degradation associated with multi-dose bottles.
Q: Can dosing frequency be reduced to once daily?
A: No. Twice-daily administration is required to sustain effective intraocular cyclosporine concentrations and achieve consistent anti-inflammatory control. Dose reduction or intermittent use may compromise therapeutic efficacy and should only be adjusted under direct ophthalmologic guidance.